Nasdaq · Healthcare
Amphastar Pharmaceuticals, Inc. (AMPH)
As-reported financials and recent SEC filings for Amphastar Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$719.9M
Net income
$98.1M
Net margin
13.6%
Diluted EPS
$2.03
ROE
12.4%
P/E (TTM)
13.1×
Market cap
$960.3M
Debt / equity
0.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M |
| Gross profit | $356.1M | $373.9M | $351.1M | $248.9M | $199.7M |
| Operating income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M |
| Net income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M |
| Diluted EPS | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →8-K2026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →10-Q2026-05-07
View on EDGAR →Go deeper on AMPH
Search Amphastar Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.